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Segregation Analysis of Plasma Apolipoprotein B 
Levels in Familial Combined Hyperlipidemia
S J.H . Bredie, J. van Drongelen, L.A. Kiemeney, P.N.M. Demacker, T.I-I. Beaty, A.F.H. Stalenhoef
Abstract Familial combined hyperlipidemia (FCH) is a heri­
table lipid disorder that is associated with an increased risk of 
premature cardiovascular disease. An elevated plasma apo­
lipoprotein (apo) B concentration is reported to be a diagnostic 
feature of the disorder. Recently we demonstrated a strong rela­
tion between plasma apoB concentrations and the cholesterol 
concentration in VLDL plus LDL, both elevated in FCH fami­
lies. Therefore, examination of the inheritance of elevated 
plasma apoB levels in FCH families may reveal important infor­
mation about the mechanism responsible for the aggregation of 
elevated plasma lipids in FCH. This study included 663 Dutch 
family members in 40 families ascertained through FCH 
probands. Plasma apoB concentration correlated significantly 
with apoB-related cholesterol both in the probands and the rela­
tives (r=.83 and r=.90, respectively). Adjustment for age, sex, 
body mass index, and smoking habits accounted for 35.7% of
the variation in apoB levels, and there was strong familial 
aggregation in adjusted apoB levels in these families. Complex 
segregation analysis was performed to determine the mechanism 
of inheritance behind this familial aggregation. The aggregation 
of elevated apoB levels was best explained by a major gene 
effect inherited by a codominant mechanism. Estimated mean 
apoB levels for the three supposed genotypes AA, AB, and BB 
were 111.5, 126.7, and 165.7 mg/dL, respectively, with relative 
frequencies of 43.5%, 44.9%, and 11.6%, respectively. In con­
clusion, despite assumed metabolic and genetic heterogeneity of 
FCH, there is clear evidence for a single gene effect on apoB 
concentrations in families ascertained through FCH. Linkage 
studies based on this analysis may further clarify the molecular 
basis of the apoB regulation in these families. {Arterioscler 
Thromb Vase Biol. 1997:17:834-840.)
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am ilia l combined hyperlipidemia is the most 
common form of heritable lipid disorders and 
is associated with cardiovascular disease.1 This 
multiple phenotype hyperlipidemia is characterized by 
elevations of the total plasma cholesterol concentration 
and/or the plasma triglyceride concentration, conse­
quently resulting in the presence of different lipid phe­
notypes in first-degree relatives. Furthermore, an ele­
vated plasma apoBlOO concentration, a decreased H D L  
concentration, and a preponderance of small, dense LD L  
particles are observed. Initially, FCH was thought to be 
inherited as a single gene disorder with a major gene 
effect on triglyceride levels.1 Recently this was sup­
ported by a segregation analysis in 55 British FCH fam i­
lies.2 Other studies, however, have shown FCH to be a 
more heterogeneous lipid disorder, comprising features 
of the insulin resistance syndrome, hyperapobetalipopro- 
teinemia, and fam ilia l dyslipidemic hypertension, 
which in turn are all associated with the presence of 
small, dense L D L .6 Still, the absence o f a specific 
metabolic or genetic marker complicates the diagnosis of 
FCH in individual patients.
In FCH, the hyperlipidemia is caused by hepatic over­
production of VLDL apoBlOO.7'8 Consequently, elevated 
levels o f apoB-containing lipoproteins (ie, ID L  and LD L
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particles) are observed. A delayed clearance of the 
triglyceride-rich apoB-containing lipoproteins, in part 
caused by impaired lipoprotein lipase activity, may mod­
ify the lip id phenotypic expression.9,10 Elevated lipid 
levels in FCH reflect elevated V LD L  and LDL choles­
terol concentrations, which correspond to an increase in 
respective particle numbers.8'11’12 Since each VLDL and 
LDL particle always contains one apoB molecule per 
particle, a strong correlation can be expected in FCH 
between total plasma apoB and its related cholesterol in 
V LD L  and L D L  particles. On this basis, the individual 
plasma apoB concentration represents the actual VLDL 
and LD L  concentrations, which may show some vari­
ability in time in FCH patients.11
Studies have also shown the association between ele­
vated apoB levels and cardiovascular disease, which is 
a feature o f FCH as w e ll.1416 Some studies show that 
the apoB level is a better predictor of premature cardio­
vascular disease than the plasma lipids are.17,1 * Com ­
plex segregation analyses demonstrated familial aggre­
gation o f elevated apoB levels in families presenting 
premature cardiovascular disease, families with fam il­
ial hyperlipidemia, and healthy volunteers, |l,'2il but con­
clusions about the specific genetic mechanism were 
contradictory to date. This may be the reason that link­
age studies could not identify conclusively the locus 
responsible for the elevation of apoB levels,20,27 ,(l 
although some gene markers showed some associa­
tion.31 Before further linkage analyses with candidate 
genes can be undertaken, it is critical to have a better 
model o f inheritance.
In the present study, segregation 
ined to explain the familial clustering of elevated apoB 
levels measured in individuals from 40 well-defined 
Dutch FCH families. Single gene effects and polygenic 
components were tested by using class D regressive
ms were exam-
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Selected Abbreviations and Acronyms
AIC = Akaike’s information criterion 
apo = apolipoprotein 
BMI = body mass index 
FCH = familial combined hyperlipidemia 
SAGE = Statistical Analysis lor Genetic Epidemiology
models described by Bonney,32 as implemented in the 
SAGE package.
Methods
Study Population
The FCH pedigrees considered here have been studied for 
inheritance of LDL subfraction profiles.13 The families were 
ascertained through probands exhibiting a combined hyperlipid- 
emia with both plasma cholesterol and triglyceride concentra­
tions above the 90th percentile, adjusted for age and sex, as 
obtained from the Prospective Cardiovascular Münster (PRO­
CAM) Study.34 These values were consistent over several mea­
surements in which the probands had not been given any lipid- 
lowering drugs. Families were included when a multiple-type 
hyperlipidemia with levels of total plasma cholesterol and/or 
triglycerides above the 90th percentile was present. Thus, 
besides the proband presenting with combined hyperlipidemia, 
at least one first-degree relative exhibited hypercholesterolemia 
or hypertriglyceridemia.
All probands were tested for an underlying cause of their 
hyperlipidemia (ie, diabetes mellitus, hypothyroidism, and he­
patic or renal impairment). The presence of one of these causes 
excluded the subjects and their families from further analysis. 
None of the probands in these families was homozygous for the 
apoe2 allele and none of the first-degree relatives had tendon 
xanthomata. In addition, to refine the selection procedure, the 
95th percentile for plasma cholesterol and triglycerides was 
used if the BMI exceeded 30 kg/nr or an alcohol consumption 
of more than two units (one unit representing one consumption) 
per day was present.
In total, 40 multi generational families (two to four genera­
tions; pedigree size ranges from 7 to 104 family members 
including spouses) were included in this study, containing 40 
FCH probands and 623 family members. All individuals were 
whites above the age of 10 years. Everyone filled out a question­
naire to collect information on medical status, medication use, 
alcohol intake, and smoking habits. The study protocol was 
approved by the ethics committee of the University Hospital of 
Nijmegen.
apoB concentrations were determined by immunonephelo- 
metry.36 To achieve accurate results in relation to the Centers for 
Disease Control Standardization Program, obtained values were 
recalculated, on the basis of an exchange of sera with Dr S. Mar- 
covina (Northwest Lipid Research Laboratory, Seattle, Wash), 
by the regression formula y=0.70.v+143 (where v is the corrected 
plasma apoB value).
Statistical Analysis
Pearson correlation coefficients were calculated for the rela­
tion between crude plasma apoB values and apoB-related 
cholesterol in VLDL plus LDL. Subsequently, multiple linear 
regression was used to examine the association between the 
apoB level and age, sex, BMI, smoking habits, and alcohol 
intake in comparison with other reports.IU,2I,23"2(’ Based on the 
results of this analysis, those eovariates that significantly influ­
enced apoB level were selected. Given this regression model, 
predicted apoB levels were calculated and residual values com­
puted by subtracting each individual’s apoB level from the pre­
dicted value. These residuals represent the fraction of the apoB 
level that is not predicted by the selected environmental vari­
ables but may represent the genetic contribution to the apoB
level. Because these residuals can be positive or negative, the 
mean apoB level was added back in and this adjusted apoB level 
was used in further analysis.
Segregation Analysis
To investigate the role of genetic and environmental influ­
ences on apoB levels, a series of class D regressive models32 
available in the SAGE program (release 2.2) was used. The 
models assume that variation among individuals for a quantita­
tive trait is the result of a major gene effect and residual varia­
tion that may reflect both familial correlations and individual 
variation.24 A “general model” describes the distributions of 
apoB levels in terms of the independent contribution of a single 
factor with a major effect, residual familial correlations, and 
nongenetie effects.22 This general model emanates from two 
alleles at a single locus (denoted A and B), resulting in three
possible “types” ol individuals (AA, AB, and BB), termed 
“ousiotypes.”37 The mean apoB value associated with each 
ousiotype is denoted haa, Mab, and p«Bi with a variance o2
mayassumed equal among all three types. The ousiotype 
be attributable to a genetic or environmental factor. The parame­
ter p is defined as the frequency of allele A; q=(l-p) equals the
frequency of allele B. Founder individuals are assumed to come 
from a population in Hardy-Weinberg equilibrium. Individuals 
characterized by the types AA, AB, and BB are assumed to
transmit the allele A with probabilities Taa» Tab. mu* 
respectively. These transmission probabilities are used to calcu­
late the probabilities of all three types for individuals whose
Plasma
After an overnight fast and a withdrawal of lipid-lowering 
medication for at least 4 weeks, blood was drawn by venipunc­
ture into EDTA-eontaining evacuated lubes. Nonlocal partici­
pants were visited at their homes, and blood was transported 
directly to the laboratory. Plasma was isolated within 3 hours 
for determination of the lipid and lipoprotein levels.
Measurement of Lipid, Lipoprotein, and Apolipoprotein Levels
VLDL was isolated from whole plasma by ultracentrifugation 
at d= 1.006 g/mL for 16 hours at 36 000 rpm in a fixed rotor 
(TFT 45.6 rotor, Kontron), in a Beckman L7-55 ultracenirifuge 
(Beckman). HDL cholesterol was determined by the polyethyl­
ene glycol 6000 method.35 LDL cholesterol was calculated by 
subtraction of VLDL cholesterol and HDL cholesterol from 
total plasma cholesterol. Respective cholesterol and triglyceride 
concentrations were determined by enzymatic commercially 
available reagents (Boehringer Mannheim, catalog No. 237574 
and Sera, Miles, catalog No. 6639, respectively). Total plasma
parents are in the pedigree. In addition, the parameters ps,„ p|)t„ 
pmn, pro, and pss denote spouse, parent-ofl'spring, mother-off- 
spring, father-offspring, and sib-sib correlations, respectively. 
In this setting, the parent-offspring correlation provides an esti­
mate of the polygenic herilability (h), ie, lr=2Pp„. cr'/crV. 
where is the total variance and a2 is the variance conditional 
on the restricted model (assuming Ppi)=Pss). Hypotheses were 
tested by comparing the general model with various submodels 
in which certain parameters were restricted to specific values. 
The “major environmental model” restricts Taa^ai^Tui^P- In 
this model, the prior probability of an offspring having a certain 
ousiotype is completely independent of parental ousiotypes. 
Mendelian models constrain these segregation probabilities Taa> 
Tab, and Tub to be 1.0, 0,5, and 0.0, respectively, The most gen­
eral Mendelian model is a “codominant” model in which each 
ousiotype has a separate mean. The “dominant model” further 
restricts Maa=Mab, while the recessive model restricts Mah-Miih- 
Submodels containing Ppo, P„u„ P|„( and Fss equal to zero are 
equivalent to restricting the “polygenic component” to zero. 
Restricted models are compared with the general model by 
using the likelihood ratio test. For nonhierarchieal models, AIC'
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Table 1. Characteristics of the Study Population
Probands Family Members Total
(n=80) (n=583) (n=663)\
Characteristics Mean SD Mean SD Mean SD
Age, y 54.6 11.4 40.8 16.6 42.4 16.6
BMI, kg/m2 26.7 3.8 24.4 3.7 24,7 3.8
Crude apoB, mg/dL 175,8 40,7 127,8 37.0 133.8 40.7
Adjusted apoB, mg/dL 156.9 43.1 130.7 29.3 133.8 32.3
BMI was missing for 6 probands and 8 family members; crude apoB levels were missing for 
7 probands and 72 family members; and adjusted apoB levels were missing for 13 probands 
and 78 family members.
was used to compare the fit of the models. For a given model, 
AIC=-21n(L)+2 • x (where x is the number of parameters esti­
mated in the model). The model with the lowest AIC is consid­
ered the most parsimonious model,™
Segregation analysis was performed on 40 families that 
included 825 individuals, although 162 individuals had missing 
data (these primarily included dead family members linking 
other relatives). In this study, no normalizing transformation 
was performed because analysis of untransformed data is easier 
to interpret and can be compared more easily with the published 
studies. In addition, normalizing transformations of a biologi­
cally skewed variable may lead to a large reduction in the power 
to detect a major gene when one exists.39 Families were selected 
through two affected probands. Consequently, the lipid inclu­
sion criteria (ie, both plasma cholesterol and triglyceride levels) 
of probands versus nonprobands showed large differences 
(Table 1). Therefore, ascertainment correction was undertaken 
by conditioning the phenotypes of family members on those of 
the affected primary probands and that of one extra individual 
with elevated lipid levels per pedigree.33
Results
Study Population
The study included 663 individuals aged between 10 
and 88 years. The correlation between crude plasma apoB 
concentration and apoB-related cholesterol concentration 
(ie, VLDL plus LDL cholesterol), both for the 40 probands 
plus 40 extra affected subjects of each family and for the 
remaining relatives, is presented in Fig 1. In both groups, a 
significant correlation was observed (r=.B3, Pc.0001 and 
r=.90, Pc.0001, respectively). Characteristics of the study 
population are presented in Table 1. BMI values varied 
between 13.6 and 40.9 kg/m2; crude apoB levels, between 
60 and 298 mg/dL; and the adjusted apoB levels, between 
42.3 and 277.7 mg/dL. Significant differences between 
probands and family members were seen in mean values of 
both crude and adjusted apoB levels.
Adjustment of the ApoB Level
Nonlipid eovariates (ie, age, age2, sex, BMI, smoking 
habits [0=not smoking, l=one or more cigarettes per 
day], and alcohol consumption [0=no alcohol consump­
tion, l=one or more units per day]) were examined in 
association with plasma apoB level. Table 2 shows the 
eovariates and their regression coefficients used in the 
adjustment of the apoB levels. Age2 and alcohol con­
sumption were excluded from the adjustment procedure 
because they did not contribute significantly. Although 
in this study sex was not significantly associated with 
apoB, it was included in the adjustment procedure to 
make our results more comparable with other studies. 
The variables combined explained 35.7% of the varia­
tion in apoB levels.
Segregation Analysis
In a first segregation analysis on the total study popu­
lation, the data were consistent with two different mod­
els of inheritance: (1) a codominant major gene effect 
explaining 44% of the variance in apoB levels, with an 
insignificant polygenetic component of h2= l% , and (2) 
an environmental model explaining 16% of the apoB 
level variance, with a polygenetic component of lr= 
(data not shown). This ambiguous result may have been 
caused by either genetic heterogeneity among these 40 
pedigrees, yielding a mixture of different mechanisms 
influencing apoB levels, or by extreme apoB levels in 
certain families or particular individuals.
To evaluate the extent to which each family supported 
one model over the other, the -21n(L) scores of both an
environmental model a n d a m i n a n t
(-21n[L|c) were calculated for each family. The 
ratio -2in(L[j/Lc) measures the extent to which each 
family favored one or the other model.l‘,,24,4twl Families
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T a b le  2. (3 and SE for the Four Variables Used in a Mul­
tiple Linear Regression Model to Adjust the Crude 
Plasma ApoB Level
Variables p SE P
Age, y 1.05 0.09 .0001
BMI, kg/m2 2.73 0.40 .0001
Sex, F -3.27 2.74 .2334
Smoking, >1 cigarette per day 13.55 3.00 .0001
that favored an environmental model would have a 
-21n(LE/Lc) ratio <0, and families with a -21n(LE/Lc) 
>0 favored a codominant model. As shown in Fig 2, the 
distribution of the likelihood ratios was centered around 
zero, suggesting most families cannot discriminate 
definitively between these models. The procedure sepa­
rated 19 families favoring an environmental model and 
21 families favoring a codominant model. One family, 
however, seemed to give an extreme preference to the 
environmental model (-21n[LE/Lc]=-I3.5). This partic­
ular family (containing 12 subjects in three generations) 
included the individual with the highest adjusted apoB 
level and was excluded from further analysis.
The results of a second series of analyses testing the 
different genetic models on the 39 remaining pedigrees 
are shown in Table 3. A ll models assumed a single corre­
lation among parents and offspring ( P po) ,  which 
appeared to be equal to the sib-sib correlation (P ss)- 
Therefore, all submodels were assumed to have a single 
correlation for first-degree relatives (P po=Pss)- The best- 
fitting one-distribution model (model 4) showed 
insignificant spouse correlations (Psp=-0.14±0.07) and 
significant residual fam ilial correlations (Ppt^Pss12
0.15±0.03). Using this familial correlation, the polyge- 
netic heri[ability was estimated to be h“=2Ppo • cr/C-t- 
0.29, which is compatible with published estimates from 
other studies. The non-Mendelian two-distribution 
model (model 6) showed a significant improvement of 
the -21n(L). The three-distribution non-Mendelian 
model (model 7) gave no further improvement of the fit. 
Inclusion of a two-distribution Mendelian mechanism 
(model 9) showed a significant improvement of the 
-21n(L) compared with model 4. The two-distribution 
Mendelian models (models 8 and 9) looked very similar 
to the two-distribution non-Mendelian models
and 6), with Psp=-0.11±0.10 and Ppo=Pss=0.22±0.05.
Extension of a two-distribution Mendelian model (model 
9) to a three-distribution Mendelian model (model 11) 
revealed a significant improvement of the -21n(L). The 
analysis presented a general model very similar to the 
best-fitting codominant model (model 11). Although the 
excluded family had a substantial influence on the - 
21n(L) used to select the most parsimonious model, no 
major differences were seen in the parameter estimates. 
Comparison of the -21n(L) scores of submodels against 
the general model (model 12) showed that models 1, 2, 
3, 4, 7, 8, and 9 could be strongly rejected (Pc.001), 
while models 5, 6, and 10 could only be weakly rejected 
(Pc.05). Only model 11 could not be rejected. Rejected 
environmental models 5, 6, and 7 did not contradict the 
most parsimonious model (model 11), because they 
showed that variation in apoB levels was strongly 
explained by a genetic component (Ppo=P.ss=0.24±0.05 to 
0.25±0.05). Comparison of models 5, 6, and 7 with 
model 11 demonstrated that the significant familial cor­
relation in apoB levels was absorbed by the inclusion of 
a codominant mechanism of inheritance. Therefore, the 
segregation of elevated apoB levels in 39 of the 40 FCH 
families was best explained as the result of a codominant 
major gene effect. Based on ousiotype variance (a2), the 
codominant model could roughly account for [a2(model 
l)-<r2(model 1 l)]/a2(model l)=(821.4-442.6)/821.4= 
46% of the genetic variance in plasma apoB.
Discussion
In the present study, a segregation analysis was per­
formed to examine genetic mechanisms that could 
explain the familial clustering of elevated apoB levels as 
observed in 663 individuals from 40 well-defined Dutch 
families. These families were ascertained through FCH, a 
common hyperlipidemia associated with premature car­
diovascular disease. The observed Mendelian mechanism 
with a codominant mode of inheritance for the segrega­
tion of elevated plasma apoB levels in this study agrees 
very well with the reported inheritance of apoB levels in 
other populations containing families of patients with 
coronary artery disease and families with familial dyslip­
idémie hypertension.20’21’24'25 Such families probably also
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T a b l e  3. Segregation Analysis of Adjusted Plasma ApoB Levels in 651 Subjects of 
39 FCH Families
Model
1. Sporadic
2. Sporadic, Psp
3. Polygenic, Ppa=Pss
4. Polygenic, Psp, Ppo=PSs
5. Environmental, Ppo=Pss
6. Environmental, Psp, Ppo=PSs
7. Environmental, Psp, Ppo=Pss
8. A dominant, Ppo=Pss
9. A dominant, Psp, Ppo=Pss
10. Codominant, Ppo=Pss
11. Codominant, Psp, Ppo=Pss
12. General, Psp, Ppo=Pss
P Maa Ha Mbs
[1.0] 130.6±1.3 = H aa =Maa 821.4±52.2
[1.0] 130.8±1.2 =H aa =Maa 814.9±51.9
[1.0] 126.8±1.9 =M aa =H aa 807.1±53.7
[1.0] 127.7±1.8 =M a a =Maa 796.2±52.3
,86±.04 125.4±1.9 = H a a 201.4±13.3 714.4±52.5
.85±.04 125.8±1.8 =M aa 196.5±13.4 703.3±52.7
.85±.04 125.8±5.4 125.8±14.7 196.5±13.4 703.4±52.7
.88±.04 125.2±2.0 = H aa 199.8±15.8 724.6±56.1
.87±.05 125.6±2.0 = H aa 193.9±17.8 718.8±59.6
.67±.06 110.5±3.0 127.4±3.4 166.0±5.1 441.5±47.4
.66±.06 111.5±3.0 126.7±3.5 165.7±5.2 442.6±47.2
,75±.06 110.3±3.2 128.6±4.5 167.7±5.4 413.2±61.4
ApoB was adjusted for age, gender, BMI, and smoking habits. Values In brackets are restricted. 
"¿<.05 vs general model. 
tP<.01 vs general model,
contain patients who satisfy the criteria for FCH. On the 
other hand, the found mechanism of inheritance is not in 
contradiction to the previously reported major gene effect 
on plasma triglyceride levels,1,2 because VLDL particles, 
which carry most of the total triglycerides, show a con­
sistent composition of lip ids and apoB protein in 
FCH .8-11'12
Total plasma apoB was determined by immunoneph- 
elometry, and obtained values were adjusted for varia­
tion due to age, sex, and smoking habits before the seg­
regation analyses.19'26 In the present study, BM I was also 
shown to be highly correlated with apoB levels.
Because a first segregation analysis could not discrim­
inate conclusively between two models of inheritance, a 
more detailed analysis was performed on each family. In 
contrast to 39 other families, 1 family seemed to have 
an extreme preference for a two-distribution non- 
Mendelian model. Without the exclusion of this particu­
lar family, the segregation analyses yielded results that 
were not interpretable, ie, several models gave -21n(L) 
that were lower than the —21n(L) of the general model. 
This might have led to an incorrect interpretation that 
one clear segregation pattern does not exist for plasma 
apoB. Furthermore, the exclusion of this single outlying 
family in a second segregation analysis influenced only 
the -21n(L) scores and through these the selection of the 
most parsimonious model, whereas estimates of model- 
specific parameters were remarkably consistent. There­
fore, this family can be seen as an indication of rare het­
erogeneity, also observed in other family samples.23'25
Both our first and second segregation analyses 
show ed a s ig n if ic a n t fa m il ia l co rre la tio n  o f  
Ppo=Pss=0-24 (model 7), which appeared not to be in flu ­
enced by the excluded family. This estimated correla­
tion is comparable to that reported by others (0.13 to 
0.47).23,24 Although examined in completely different 
study populations, most studies reported a codominant 
model as the most parsimonious fit on their apoB 
data.20'22,24,25,31 A few studies, however, preferred a 
dominant or recessive model.19,23,26 The estimated rela­
tive frequency of the “low” apoB allele at 66% is in 
agreement with other reports.211'22,24,25,31 These consis­
tent findings suggest that genetic control of apoB levels 
is comparable in subjects with different dyslipidemia 
phenotypes. Some of the remaining differences in the 
results may be explained by the large differences in
ascertainment criteria of the analyzed study populations, 
since studies ascertained families through probands who 
suffered from C A D ,19,21,25 who were patients of a lipid 
c lin ic ,22,23 who were submitted to elective coronary 
angiography,24 or who had a coincident detection of 
CA D  in the fam ily .20,31 This study analyzed its sample 
after correction on ascertainment, because plasma apoB 
concentrations strongly correlated with plasma choles­
terol and triglyceride levels. Although the influence of 
ascertainment bias on the segregation analysis is still a 
subject o f debate, unadjusted analyses may indicate the 
existence of a major gene effect when one is absent or 
may bias toward a dominant expression when it actually 
should be a recessive one.42
FCH is caused by hepatic overproduction of VLDL 
apoBlOO, subsequently leading to elevated levels of 
apoB-containing IDL and LDL particles, of which the 
latter are predominantly smaller and denser compared 
with normolipidem ic subjects.11,14 The finding of a 
genetic mechanism for elevated apoB levels in this FCH 
population suggests that there is genetic control of he­
patic V L D L  apoB production and that additional 
metabolic processes responsible for diminished clear­
ance of apoB-containing particles, associated with muta­
tions in  the lip o p ro te in  lipase  gene910 and the 
apoA l/C III/A IV  gene cluster,43,44 are subordinate to this 
V LDL apoB overproduction. Thus, metabolic processes 
associated with V LD L apoB overproduction, such as 
increased delivery of free fatty acids to iiver cells45 or 
dysregulation of the action of microsomal triglyceride 
transfer protein required for assembly and secretion of 
hepatic V LD L  apoB,4h may have a genetic basis.
Recently, we demonstrated Mendelian inheritance of 
dense LDL subfraction profiles in these same FCH fami­
lies.33 It appeared that the LDL subfraction profile was 
strongly related to the plasma apoB concentration, which 
raises the question whether the observed inheritance of 
the LD L  subfractions more likely reflects the segrega­
tion of a trait in which affected subjects have elevated 
concentrations of apoB, as demonstrated in the present 
study. The few available reports, however, suggest that 
LD L  subfraction profile phenotype and plasma apoB 
level genotype are separate Mendelian traits in FCH.-'47 
Further analysis in which the LDL subfraction profile is 
considered independent of the genetic influence of apoB 
may elucidate this complicated issue.
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T a b l e  3 . Continued
^AA ^AB ^BB Psp Ppo—Pss 2ln(L) AIC X2 (df)
« •  • 1 » • • • • [.0] [.0] 4736.3 4740.3 68.7 (8)t
• i  ■ » • ♦ * * • -.20±.08 [.0] 4729.6 4735.6 62.0 (7)t
• * * t  • • » « « 10] .17±.04 4701.1 4707.1 33.5 (7)t
< i  • * * • •  • ♦ —. 14±,07 .15±.03 4697.4 4705.4 29.8 (6)f
=p =P =p 1-0] .25±.05 4682.1 4692.1 14.5 (5)*
=p =P =p —.11±.10 .24±.05 4680.9 4692.9 13.3 (4)*
=p =P =p — .  11 ±.10 .24±.05 4680,9 4694.9 13.3 (3)f
[1.0] [.5] [•0] [.0] .24±.04 4690.9 4700.9 23.3 (5)f
[1.0] [•5] [.0] —.11±.10 ,22±.05 4689.6 4701.6 22.0 (4)f
[1.0] [-5] [.0] [.0] (.0) bnd. 4678.7 4688.7 11.1 (4)*
[1.01 [•5] [•0] -.20±0.10 (.0) bnd. 4674.7 4684.7 7.1 (3)
.91±,05 ,35±,10 .09±.13 -,18±.11 ,00±.06 4667.6 4687.6 Reference
In conclusion, there is a clear familial aggregation of 
elevated apoB concentrations that significantly corre­
spond to the lipid phenotype in FCH families. Segrega­
tion analysis provides evidence that this aggregation is 
well explained by a single major gene effect with a 
codominant expression. Using these findings, linkage 
analysis can be used to explore the molecular defect 
involved in apoB regulation in FCH families.
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